Organogenesis Holdings Inc. (NASDAQ:ORGO) Insider Lori Freedman Purchases 100,863 Shares

Organogenesis Holdings Inc. (NASDAQ:ORGO) insider Lori Freedman purchased 100,863 shares of the company’s stock in a transaction dated Wednesday, June 4th. The shares were purchased at an average price of $2.82 per share, for a total transaction of $284,433.66. Following the completion of the purchase, the insider now owns 695,058 shares of the company’s stock, valued at approximately $1,960,063.56. This trade represents a 16.97% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Lori Freedman also recently made the following trade(s):

• On Friday, June 6th, Lori Freedman purchased 9,022 shares of Organogenesis stock. The shares were purchased at an average price of $2.99 per share, for a total transaction of $26,975.78.
• On Thursday, June 5th, Lori Freedman purchased 142,379 shares of Organogenesis stock. The shares were purchased at an average price of $2.91 per share, for a total transaction of $414,322.89.

Organogenesis Trading Up 5.2%

Shares of ORGO opened at $3.03 on Friday. The company has a current ratio of 3.09, a quick ratio of 2.74 and a debt-to-equity ratio of 0.21. The firm’s 50-day moving average is $3.82 and its two-hundred day moving average is $3.85. Organogenesis Holdings Inc. has a twelve month low of $2.28 and a twelve month high of $6.71. The firm has a market capitalization of $384.37 million, a P/E ratio of -50.50 and a beta of 1.85.

Organogenesis (NASDAQ:ORGO) last issued its earnings results on Thursday, May 8th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.17). Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. The company had revenue of $86.69 million for the quarter, compared to analyst estimates of $90.77 million. On average, research analysts predict that Organogenesis Holdings Inc. will post -0.07 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley upped their target price on shares of Organogenesis from $4.00 to $6.00 and gave the stock an “equal weight” rating in a research report on Wednesday, March 5th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Merit Financial Group LLC acquired a new position in Organogenesis during the first quarter worth about $45,000. Virtu Financial LLC acquired a new stake in shares of Organogenesis in the fourth quarter valued at approximately $38,000. Victory Capital Management Inc. acquired a new stake in shares of Organogenesis in the first quarter valued at approximately $67,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of Organogenesis in the first quarter valued at approximately $77,000. Finally, Ieq Capital LLC acquired a new stake in shares of Organogenesis in the first quarter valued at approximately $79,000. 49.57% of the stock is currently owned by institutional investors and hedge funds.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.